SUN PHARMACEUTICAL IND L (524715) — Latest Corporate Announcements
₹1,746.4
₹-24.30 (-1.37%)
Market Cap
₹4,19,019.86 Cr
P/E Ratio
34.65
52W Range
₹1583.7 – ₹2046.9
Board Meeting Intimations
📅 Scheduled Board Meeting & Agenda
Meeting Date: 30-Oct-2026
Agenda / Purpose: Financial Results
Timeline: In 15 days
Corporate Actions & Regulatory Filings
Board Meeting Intimation for consideration and approval the Unaudited Financial Results for the quarter and half year ended 30 September 2026
Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Intimation for Consideration And Approval The Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2026
Sun Pharmaceutical Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Sun Pharmaceutical Industries Ltd - 524715 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Sun Pharmaceutical Industries Limited has informed the Exchange about Credit Rating
Announcement under Regulation 30 (LODR)-Credit Rating
Sun Pharmaceutical Industries Limited has informed the Exchange about Resignation of Director/KMP/SMP
Resignation of Director of the Company
Announcement under Regulation 30 (LODR)-Resignation of Director
Board Meeting Outcome for Outcome Of The Board Meeting Held On 12 October 2026
Board Meeting Intimation for Consideration And Approval Of The Issuance Of Listed, Rated, Unsecured, Redeemable, Non-Convertible Debentures
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Newspaper Publication
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Newspaper Publication
ESG Overview For FY 2025-26
Completion And Result Of Postal Ballot Dated 25 August 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Receipt Of Approval Of The Shareholders For Reclassification Of Shareholder Category
Financial Results (Quarterly & Annual)
| Quarter / Period | Meeting / Outcome Date | Status | Filing Details |
|---|---|---|---|
| Quarter Ended 30-Sep-2026 (Q2 FY27) | 30-Oct-2026 | Scheduled Upcoming | Board Meeting Intimation for consideration and approval the Unaudited Financial Results for the quarter and half year ended 30 September 2026 |
| Quarter Ended 30-Jun-2026 (Q1 FY27) (STD & CONSOL) | 31 Jul 2026 | Declared |
Unaudited Standalone And Consolidated Financial Results For Q1 Of FY 2026-27
📄 View Quarter Ended 30-Jun-2026 (Q1 FY27) (STD & CONSOL) Results PDF ↗ |
| Year Ended 31-Mar-2026 (Q4 FY26) | 22 May 2026 | Declared | Dividend & Results |
| Quarter Ended 31-Dec-2025 (Q3 FY26) | 31 Jan 2026 | Declared | Dividend & Results |
| Quarter Ended 30-Sep-2025 (Q2 FY26) | 05 Nov 2025 | Declared | Results |
| Quarter Ended 30-Jun-2025 (Q1 FY26) | 31 Jul 2025 | Declared | Results |
| Year Ended 31-Mar-2025 (Q4 FY25) | 22 May 2025 | Declared | Dividend & Results |
| Quarter Ended 31-Dec-2024 (Q3 FY25) | 31-Jan-2025 | Declared | To consider and approve the financial results for the period ended December 31, 2024 and Interim dividend for FY 2024-25 |
| Quarter Ended 30-Sep-2024 (Q2 FY25) | 28-Oct-2024 | Declared | To consider and approve the financial results for the period ended September 30, 2024 |
| Quarter Ended 30-Jun-2024 (Q1 FY25) | 01-Aug-2024 | Declared | To consider and approve Quarterly Financial Results for Q1 of FY 2024-25 |
| Year Ended 31-Mar-2024 (Q4 FY24) | 22-May-2024 | Declared | To consider and approve the audited financial results for the period ended March 31, 2024 and final dividend |
| Quarter Ended 31-Dec-2023 (Q3 FY24) | 31-Jan-2024 | Declared | To consider and approve the financial results for the period ended December 31, 2023 and interim dividend |
Track Related Peer Equities
Related Research Guides & Regulatory Playbooks
Frequently Asked Questions about SUN PHARMACEUTICAL IND L BSE Disclosures
What is the latest BSE announcement by SUN PHARMACEUTICAL IND L?
The latest BSE disclosure by SUN PHARMACEUTICAL IND L (SUNPHARMA), filed on 30-Oct-2026 , is: "Board Meeting Intimation for consideration and approval the Unaudited Financial Results for the quarter and half year ended 30 September 2026". Bsenexus tracks every official filing for SUN PHARMACEUTICAL IND L with AI-powered summaries on its announcements feed.
When is SUN PHARMACEUTICAL IND L's next board meeting?
SUN PHARMACEUTICAL IND L has a board meeting scheduled for 30-Oct-2026 (in 15 days) to consider: Financial Results.
When does SUN PHARMACEUTICAL IND L declare quarterly results?
Under SEBI (LODR) Regulation 33, listed companies submit quarterly unaudited results within 45 days of the quarter ending, and annual audited figures within 60 days. SUN PHARMACEUTICAL IND L's recent results history is tabulated above. Track scheduled board meetings on the Bsenexus Results Calendar.